All In Biotech

Drug Trial Radar · NCT07739888

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Dec 30, 2027

Primary completion

Dec 30, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in eligible patients who completed the double-blinded core part of CMAA868A2302 (ANT-010/NCT05712200)

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • AbelacimabBiological

    Abelacimab provided as liquid in vial (150 mg/mL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first ISTH major Bleeding eventsTime frame: Up to 3 years
  2. Time to first BARC type 3c/5 bleedingTime frame: Up to 3 years
  3. Number of participants with ISTH major or CRNM bleedingTime frame: Up to 3 years
  4. Number of participants with bleedingTime frame: Up to 3 years
  5. Number of participants with TEAEs and TESAEsTime frame: Up to 3 years
  6. Number of participants with treatment discontinuations due to TEAEsTime frame: Up to 3 years
  7. Number of participants with device related AEs, SAEs, and device deficienciesTime frame: Up to 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.